From the Cleveland Clinic Foundation, Cleveland, Ohio (S.J.B., D.J.M.,
E.J.T.); Midwest Heart Research, Lombard, Ill (L.A.B.); University of
Pittsburgh Medical Center, Pittsburgh, Pa (J.E.B.B.); North Shore University
Hospital, Manhasset, NY (S.K.); Riverside Methodist Hospital, Columbus, Ohio
(B.S.G.); Crozer Chester Medical Center, Upland, Pa (A.A.J.); Baptist Medical
Center, Birmingham, Ala (E.D.C.); St Joseph Hospital, Savannah, Ga (P.C.G.);
Presbyterian Health Care Center, Albuquerque, NM (H.J.W.); High Point Regional
Hospital, High Point, NC (H.B.C.); Lenox Hill Hospital, New York, NY (J.W.M.);
and Lilly Research Laboratories, Indianapolis, Ind (M.B.E.).
Correspondence to Eric J. Topol, MD, Department of Cardiology, 9500 Euclid Ave, Cleveland Clinic Foundation, Cleveland, OH 44195. E-mail topole{at}cesmtp.ccf.org
Background—The benefit of
catheter-based reperfusion for acute myocardial infarction (MI) is
limited by a 5% to 15% incidence of in-hospital major
ischemic events, usually caused by infarct artery reocclusion,
and a 20% to 40% need for repeat percutaneous or
surgical revascularization. Platelets play a
key role in the process of early infarct artery reocclusion, but
inhibition of aggregation via the glycoprotein IIb/IIIa
receptor has not been prospectively evaluated in the setting of
acute MI.
Methods and Results—Patients with acute MI of <12 hours'
duration were randomized, on a double-blind basis, to placebo or
abciximab if they were deemed candidates for primary PTCA. The primary
efficacy end point was death, reinfarction, or any (urgent or elective)
target vessel revascularization (TVR) at 6 months
by intention-to-treat (ITT) analysis. Other key prespecified
end points were early (7 and 30 days) death, reinfarction, or urgent
TVR. The baseline clinical and angiographic variables of the 483
(242 placebo and 241 abciximab) patients were balanced. There was no
difference in the incidence of the primary 6-month end point (ITT
analysis) in the 2 groups (28.1% and 28.2%,
P=0.97, of the placebo and abciximab patients,
respectively). However, abciximab significantly reduced the incidence
of death, reinfarction, or urgent TVR at all time points assessed
(9.9% versus 3.3%, P=0.003, at 7 days; 11.2% versus
5.8%, P=0.03, at 30 days; and 17.8% versus 11.6%,
P=0.05, at 6 months). Analysis by actual
treatment with PTCA and study drug demonstrated a considerable effect
of abciximab with respect to death or reinfarction: 4.7% versus 1.4%,
P=0.047, at 7 days; 5.8% versus 3.2%,
P=0.20, at 30 days; and 12.0% versus 6.9%,
P=0.07, at 6 months. The need for unplanned,
"bail-out" stenting was reduced by 42% in the abciximab group
(20.4% versus 11.9%, P=0.008). Major bleeding occurred
significantly more frequently in the abciximab group (16.6% versus
9.5%, P=0.02), mostly at the arterial
access site. There was no intracranial hemorrhage in either
group.
Conclusions—Aggressive platelet inhibition with abciximab
during primary PTCA for acute MI yielded a substantial reduction in the
acute (30-day) phase for death, reinfarction, and urgent target vessel
revascularization. However, the bleeding rates were
excessive, and the 6-month primary end point, which included elective
revascularization, was not favorably affected.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction
Key Words: angioplasty • myocardial infarction • platelet aggregation inhibitors
This article has been cited by other articles:
 |
|
 |
|
  G. Guagliumi Emerging data and decision for optimizing STEMI management: the European perspective Eur. Heart J. Suppl., June 1, 2009; 11(suppl_C): C19 - C24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Brener The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect? J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1674 - 1676. [Full Text] [PDF]
|
|
|
|
|
|
G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, D. Kivelitz, et al. Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial Circulation, July 1, 2008; 118(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Moliterno and K. M. Ziada The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 536 - 537. [Full Text] [PDF]
|
|
|
|
|
|
M. Menichelli, A. Parma, E. Pucci, R. Fiorilli, F. De Felice, M. Nazzaro, A. Giulivi, D. Alborino, A. Azzellino, and R. Violini Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI) J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1924 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1517 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Raveendran, H. H. Ting, P. J. Best, D. R. Holmes Jr, R. J. Lennon, M. Singh, M. R. Bell, K. H. Long, and C. S. Rihal Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Mayo Clin. Proc., February 1, 2007; 82(2): 196 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
|
|
J. Saw, D. L. Bhatt, D. J. Moliterno, S. J. Brener, S. R. Steinhubl, A. M. Lincoff, J. E. Tcheng, R. A. Harrington, M. Simoons, T. Hu, et al. The Influence of Peripheral Arterial Disease on Outcomes: A Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1567 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Heer, U Zeymer, C Juenger, A K Gitt, H Wienbergen, R Zahn, M Gottwik, J Senges, and for the Acute Coronary Syndromes (ACOS) Registry I Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice Heart, October 1, 2006; 92(10): 1484 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) J. Am. Coll. Cardiol., January 3, 2006; 47(1): 216 - 235. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Circulation, January 3, 2006; 113(1): 156 - 175. [Full Text] [PDF]
|
|
|
|
 |
|
 The ADMIRAL Investigators Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study Eur. Heart J., December 1, 2005; 26(23): 2520 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Huber, R. D. Caterina, S. D. Kristensen, F. W.A. Verheugt, G. Montalescot, L. B. Maestro, F. V. d. Werf, and for the Task Force on Pre-hospital Reperfusion The Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction Eur. Heart J., October 1, 2005; 26(19): 2063 - 2074. [Full Text] [PDF]
|
|
|
|
|
|
M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Beygui and G. Montalescot The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I10 - I14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Migliorini and D. Antoniucci Patient selection bias in primary percutaneous coronary intervention trials: a critical issue Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I21 - I26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Danzi, L. Mauri, and F. Sozzi Percutaneous coronary intervention and beyond for ST-elevation acute myocardial infarction Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K26 - K30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, R. Grimaldi, and M. Chiariello Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction QJM, September 1, 2005; 98(9): 633 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brophy and L. Joseph Medical Decision Making with Incomplete Evidence--Choosing a Platelet Glycoprotein IIbIIIa Receptor Inhibitor for Percutaneous Coronary Interventions Med Decis Making, March 1, 2005; 25(2): 222 - 228. [Abstract] [PDF]
|
|
|
|
|
|
M. Gyongyosi, H. Domanovits, W. Benzer, M. Haugk, B. Heinisch, G. Sodeck, R. Hodl, G. Gaul, G. Bonner, J. Wojta, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study Eur. Heart J., December 1, 2004; 25(23): 2125 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ndrepepa, A. Kastrati, F.-J. Neumann, C. Schmitt, J. Mehilli, and A. Schomig Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting Eur. Heart J., September 2, 2004; 25(18): 1635 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goto, N. Tamura, and H. Ishida Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions J. Am. Coll. Cardiol., July 21, 2004; 44(2): 316 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Simon and M. Sakuma Platelet disaggregation: Putting time on your side in acute myocardial infarction J. Am. Coll. Cardiol., July 21, 2004; 44(2): 324 - 326. [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot, M. Borentain, L. Payot, J. P. Collet, and D. Thomas Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis JAMA, July 21, 2004; 292(3): 362 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, C.-J. Wu, C.-H. Yang, H.-W. Chang, S.-M. Chen, W.-C. Hung, and C.-L. Hang Delayed Post-Myocardial Infarction Invasive Measures, Helpful or Harmful?: A Subgroup Analysis Chest, July 1, 2004; 126(1): 38 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): 676 - 677. [Full Text] [PDF]
|
|
|
|
|
|
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): e37 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman and F. Van de Werf Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction Circulation, June 1, 2004; 109(21): 2480 - 2486. [Full Text] [PDF]
|
|
|
|
|
|
D. Antoniucci, A. Migliorini, G. Parodi, R. Valenti, A. Rodriguez, A. Hempel, G. Memisha, and G. M. Santoro Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival: A Prospective, Multicenter, Randomized Trial Comparing Infarct Artery Stenting Plus Abciximab With Stenting Alone Circulation, April 13, 2004; 109(14): 1704 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M W H Behan and R F Storey Antiplatelet therapy in cardiovascular disease Postgrad. Med. J., March 1, 2004; 80(941): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kunichika, O. Ben-Yehuda, S. Lafitte, N. Kunichika, B. Peters, and A. N. DeMaria Effects of glycoprotein iib/iiia inhibition on microvascular flow after coronary reperfusion: A quantitative myocardial contrast echocardiography study J. Am. Coll. Cardiol., January 21, 2004; 43(2): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnicka, et al. Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology Eur. Heart J., January 2, 2004; 25(2): 166 - 181. [Full Text] [PDF]
|
|
|
|
|
|
G. Melandri The Obsession With Primary Angioplasty Circulation, December 9, 2003; 108 (23): e162 - e162. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Topol, F.-J. Neumann, and G. Montalescot A preferred reperfusion strategy for acute myocardial infarction J. Am. Coll. Cardiol., December 3, 2003; 42(11): 1886 - 1889. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Mehta, K. J. Harjai, D. Cox, G. W. Stone, B. Brodie, J. Boura, W. O'Neill, C. L. Grines, and Primary Angioplasty in Myocardial Infarction (PAMI Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1739 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dangas Interventional therapy for acute myocardial infarction: respect the microvasculature J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1403 - 1405. [Full Text] [PDF]
|
|
|
|
|
|
M. Dalby, A. Bouzamondo, P. Lechat, and G. Montalescot Transfer for Primary Angioplasty Versus Immediate Thrombolysis in Acute Myocardial Infarction: A Meta-Analysis Circulation, October 14, 2003; 108(15): 1809 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P Dobesh, S. L Lanfear, J. R Abu-Shanab, J. E Lakamp, S. Gowda, and M. Y Haikal Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI Ann. Pharmacother., October 1, 2003; 37(10): 1375 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Tcheng, D. E. Kandzari, C. L. Grines, D. A. Cox, M. B. Effron, E. Garcia, J. J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, et al. Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial Circulation, September 16, 2003; 108(11): 1316 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, C.-J. Wu, H.-W. Chang, Y.-K. Hsieh, C.-Y. Fang, S.-M. Chen, and M.-C. Chen Impact of Tirofiban on Angiographic Morphologic Features of High-Burden Thrombus Formation During Direct Percutaneous Coronary Intervention and Short-term Outcomes Chest, September 1, 2003; 124(3): 962 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Eisenberg and S. Jamal Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction J. Am. Coll. Cardiol., July 2, 2003; 42(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Crouch, J. M Nappi, and K. I Cheang Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome Ann. Pharmacother., June 1, 2003; 37(6): 860 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Brener, S. G. Ellis, J. Schneider, C. Apperson-Hansen, and E. J. Topol Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry Eur. Heart J., April 1, 2003; 24(7): 630 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, M.-C. Chen, C.-J. Wu, H.-W. Chang, T.-H. Yu, K.-H. Yeh, and M. Fu Acute Myocardial Infarction With Simultaneous ST-Segment Elevation in the Precordial and Inferior Leads: Evaluation of Anatomic Lesions and Clinical Implications Chest, April 1, 2003; 123(4): 1170 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Lee, N. A. Herity, B. L. Hiatt, W. F. Fearon, M. Rezaee, A. J. Carter, M. Huston, D. Schreiber, P. M. DiBattiste, and A. C. Yeung Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial Circulation, March 25, 2003; 107(11): 1497 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Moliterno and A. W. Chan Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 49S - 54S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J., January 1, 2003; 24(1): 28 - 66. [Full Text] [PDF]
|
|
|
|
|
|
A.S Petronio, D Rovai, G Musumeci, R Baglini, C Nardi, U Limbruno, C Palagi, D Volterrani, and M Mariani Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty Eur. Heart J., January 1, 2003; 24(1): 67 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Lenderink, E Boersma, C Heeschen, A Vahanian, M.-J de Boer, V Umans, M.J.B.M van den Brand, C.W Hamm, M.L Simoons, and for the CAPTURE investigators Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA Eur. Heart J., January 1, 2003; 24(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Karvouni, D. G. Katritsis, and J. P. A. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J. Am. Coll. Cardiol., January 1, 2003; 41(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, C.-J. Wu, M. Fu, K.-H. Yeh, T.-H. Yu, W.-C. Hung, and M.-C. Chen Clinical Features and Outcome of Patients With Direct Percutaneous Coronary Intervention for Acute Myocardial Infarction Resulting From Left Circumflex Artery Occlusion Chest, December 1, 2002; 122(6): 2068 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, R. M. Califf, F. Van de Werf, J. T. Willerson, H. D. White, P. W. Armstrong, V. Guetta, W. B. Gibler, J. S. Hochman, C. Bode, et al. Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial JAMA, November 6, 2002; 288(17): 2130 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, M.-C. Chen, H.-W. Chang, C.-L. Hang, Y.-K. Hsieh, C.-Y. Fang, and C.-J. Wu Angiographic Morphologic Features of Infarct-Related Arteries and Timely Reperfusion in Acute Myocardial Infarction: Predictors of Slow-Flow and No-Reflow Phenomenon Chest, October 1, 2002; 122(4): 1322 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ribichini and W. Wijns ACUTE MYOCARDIAL INFARCTION: REPERFUSION TREATMENT Heart, September 1, 2002; 88(3): 298 - 305. [Full Text] [PDF]
|
|
|
|
|
|
E. Ronner, E. Boersma, G.-J. Laarman, G. A. Somsen, R. A. Harrington, J. W. Deckers, E. J. Topol, R. M. Califf, and M. L. Simoons Early angioplasty in acute coronary syndromes without persistent st-segment elevation improves outcome but increases the need for six-month repeat revascularization: An analysis of the pursuit trial J. Am. Coll. Cardiol., June 19, 2002; 39(12): 1924 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Constantinides, T S N Lo, M Been, and M F Shiu Early experience with a helical coronary thrombectomy device in patients with acute coronary thrombosis. Heart, May 1, 2002; 87(5): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone, C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, J. J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J. D. Carroll, et al. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction N. Engl. J. Med., March 28, 2002; 346(13): 957 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.Ph. Collet, G. Montalescot, C. Lesty, and J.W. Weisel A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots Circ. Res., March 8, 2002; 90(4): 428 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.W.G. Leebeek, E. Boersma, C.P. Cannon, F.J.J. van de Werf, and M.L. Simoons Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable Eur. Heart J., March 2, 2002; 23(6): 444 - 457. [Full Text] [PDF]
|
|
|
|
|
|
S. H. Rezkalla and R. A. Kloner No-Reflow Phenomenon Circulation, February 5, 2002; 105(5): 656 - 662. [Full Text] [PDF]
|
|
|
|
|
|
J. Mehilli, A. Kastrati, J. Dirschinger, J. Pache, M. Seyfarth, R. Blasini, D. Hall, F.-J. Neumann, and A. Schomig Sex-Based Analysis of Outcome in Patients With Acute Myocardial Infarction Treated Predominantly With Percutaneous Coronary Intervention JAMA, January 9, 2002; 287(2): 210 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R Kalra Has abciximab's ship come in?: Results from the ADMIRAL investigators and diabetic substudy The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1): 30 - 31. [Abstract] [PDF]
|
|
|
|
|
|
W. B. Batchelor, K. W. Mahaffey, P. B. Berger, E. Deutsch, S. Meier, V. Hasselblad, E. T. Fry, P. S. Teirstein, A. M. Ross, C. A. Binanay, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1608 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Vakili, R. Kaplan, and D. L. Brown Volume-Outcome Relation for Physicians and Hospitals Performing Angioplasty for Acute Myocardial Infarction in New York State Circulation, October 30, 2001; 104(18): 2171 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Hanratty, M. Ward, D. P. Chew, D. L. Bhatt, A. M. Lincoff, D. J. Moliterno, S. J. Brener, K. E. Wolski, and E. J. Topol Optimal Activated Clotting Time During Percutaneous Coronary Intervention Response Circulation, October 9, 2001; 104 (15): e83 - e84. [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, C.-J. Wu, M.-C. Chen, H.-W. Chang, K. Y.-K. Hsieh, C.-L. Hang, and M. Fu Effect of Primary Angioplasty on Total or Subtotal Left Main Occlusion : Analysis of Incidence, Clinical Features, Outcomes, and Prognostic Determinants Chest, October 1, 2001; 120(4): 1212 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G MANOHARAN and A A J ADGEY Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond Heart, September 1, 2001; 86(3): 259 - 261. [Full Text] [PDF]
|
|
|
|
|
|
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450. [PDF]
|
|
|
|
|
|
G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, J.-M. Boulenc, M.-C. Morice, L. Maillard, M. Pansieri, et al. Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction N. Engl. J. Med., June 21, 2001; 344(25): 1895 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Anderson, R. M. Califf, G. W. Stone, F.-J. Neumann, G. Montalescot, D. P. Miller, J. J. Ferguson III, J. T. Willerson, H. F. Weisman, and E. J. Topol Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2059 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Bashore, E. R. Bates, P. B. Berger, D. A. Clark, J. T. Cusma, G. J. Dehmer, M. J. Kern, W. K. Laskey, M. P. O'Laughlin, S. Oesterle, et al. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on Cardiac Catheterization Laboratory Standards: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents endorsed by the American Heart Association and the Diagnostic and Interventional Catheterization Committee of the Council on Clinical Cardiology of the AHA J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2170 - 2214. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]
|
|
|
|
|
|
R. Zahn, R. Schiele, S. Schneider, A. K. Gitt, H. Wienbergen, K. Seidl, T. Voigtlander, M. Gottwik, G. Berg, E. Altmann, et al. Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary angioplasty?: Results from the pooled data of the maximal individual therapy in acute myocardial infarction registry and the myocardial infarction registry J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1827 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zijlstra CORONARY DISEASE: Acute myocardial infarction: primary angioplasty Heart, June 1, 2001; 85(6): 705 - 709. [Full Text]
|
|
|
|
|
|
F. Van de Werf New aspects of pharmacological reperfusion: from macro- to microlysis Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C62 - C68. [Abstract] [PDF]
|
|
|
|
|
|
E. Braunwald Foreword Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A1 - A2. [PDF]
|
|
|
|
|
|
G. Montalescot, R. Choussat, and J.P. Collet Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A3 - A7. [Abstract] [PDF]
|
|
|
|
|
|
H.C. Herrmann, R.H. Li, and E.M. Ohman Facilitated percutaneous coronary intervention: results from the SPEED trial Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A26 - A34. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Le May, M. Labinaz, R. F. Davies, J.-F. Marquis, L. A. Laramee, E. R. O'Brien, W. L. Williams, R. S. Beanlands, G. Nichol, and L. A. Higginson Stenting versus thrombolysis in acute myocardial infarction trial (STAT) J. Am. Coll. Cardiol., March 15, 2001; 37(4): 985 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kaul, R. Sapra, B. Singh, D. Sudan, T. Ghose, N. S. Dixit, and H. S. Wasir Abciximab During Rescue Angioplasty After Failed Thrombolysis Asian Cardiovasc Thorac Ann, March 1, 2001; 9(1): 31 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chew, D. L. Bhatt, A. M. Lincoff, D. J. Moliterno, S. J. Brener, K. E. Wolski, and E. J. Topol Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention : Aggregate Results From 6 Randomized, Controlled Trials Circulation, February 20, 2001; 103(7): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Yip, C.-J. Wu, K.-H. Yeh, C.-L. Hang, C.-Y. Fang, K. Y.-K. Hsieh, and M. Fu Unusual Complication of Retrograde Dissection to the Coronary Sinus of Valsalva During Percutaneous Revascularization : A Single-Center Experience and Literature Review Chest, February 1, 2001; 119(2): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Roe, E. M. Ohman, A. C. P. Maas, R. H. Christenson, K. W. Mahaffey, C. B. Granger, R. A. Harrington, R. M. Califf, and M. W. Krucoff Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion J. Am. Coll. Cardiol., January 1, 2001; 37(1): 9 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Collet, G. Montalescot, C. Lesty, J. Soria, Z. Mishal, D. Thomas, and C. Soria Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 142 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade Antithrombotic Agents in Coronary Artery Disease Chest, January 1, 2001; 119(1_suppl): 228S - 252S. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, D. B. Mark, J. E. Tcheng, R. M. Califf, M. V. Bala, K. M. Anderson, L. Davidson-Ray, J. D. Knight, C. F. Cabot, and E. J. Topol Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization : Results From the EPILOG Randomized Trial Circulation, December 12, 2000; 102(24): 2923 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chew and D. J. Moliterno A critical appraisal of platelet glycoprotein IIb/IIIa inhibition J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zahn, R. Schiele, S. Schneider, A. K. Gitt, H. Wienbergen, K. Seidl, C. Bossaller, H. J. Buttner, M. Gottwik, E. Altmann, et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis: Results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registry (MIR) J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2064 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Herrmann, D. J. Moliterno, E. M. Ohman, A. L. Stebbins, C. Bode, A. Betriu, F. Forycki, J. S. Miklin, W. B. Bachinsky, A. M. Lincoff, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1489 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Quinn, D. Cox, J. B. Foley, and D. J. Fitzgerald Glycoprotein IIb/IIIa Receptor Number and Occupancy during Chronic Administration of an Oral Antagonist J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 670 - 676. [Abstract] [Full Text]
|
|
|
|
|
|
E Ronner, H.A.M van Kesteren, P Zijnen, E Altmann, P.G Molhoek, L.R van der Wieken, C.A Cuffie-Jackson, K.L Neuhaus, and M.L Simoons Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study Eur. Heart J., September 2, 2000; 21(18): 1530 - 1536. [Abstract] [PDF]
|
|